Oncology reports最新文献

Changing landscape of advanced esophageal squamous cell carcinoma: Breakthroughs in systemic therapies (Review). 晚期食管鳞状细胞癌的改变：全身治疗的突破（综述）。

IF 3.9 3区医学

Oncology reports Pub Date : 2025-10-01 Epub Date: 2025-07-19 DOI: 10.3892/or.2025.8953

Yueyue Li, Jingjing Li, Wenhui Mo, Xuanfu Xu

{"title":"Changing landscape of advanced esophageal squamous cell carcinoma: Breakthroughs in systemic therapies (Review).","authors":"Yueyue Li, Jingjing Li, Wenhui Mo, Xuanfu Xu","doi":"10.3892/or.2025.8953","DOIUrl":"10.3892/or.2025.8953","url":null,"abstract":"The treatment of advanced esophageal squamous cell carcinoma (ESCC) presents numerous challenges. Whereas conventional therapies such as chemotherapy, radiotherapy and targeted treatments have achieved some success. However, the substantial heterogeneity of the disease poses challenges in achieving comprehensive therapeutic coverage through a single treatment approach, because molecular subtyping remains insufficiently defined. Consequently, the response rate to targeted therapies is limited. Moreover, the issue of resistance to immunotherapy is becoming increasingly prominent, and reliable predictive biomarkers are lacking. Additionally, the regulatory mechanisms of the tumor microenvironment in metastatic lesions require further investigation. In recent years, the advent of immunotherapy and novel drug development has brought new hope, particularly with the clinical application of antibody‑drug conjugates, bispecific antibodies, novel immune checkpoint inhibitors, new targeted therapies, and cell and vaccine therapies, which have markedly improved patient survival. The present review summarizes the current therapeutic landscape for advanced ESCC and discusses the potential of future treatment strategies. Despite improvements in survival rates with existing treatments, the integration of emerging therapies with precision medicine may become key to future ESCC management, through driving personalized treatment approaches and multidisciplinary collaboration, and ultimately improving patient quality of life and clinical outcomes.","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"54 4","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308835/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144668059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High expression of eIF4A1 promotes angiogenesis through the NF‑κB/VEGFA pathway and predicts poor prognosis in gastric cancer. 高表达的eIF4A1通过NF - κB/VEGFA通路促进血管生成，预测胃癌预后不良。

IF 3.9 3区医学

Oncology reports Pub Date : 2025-10-01 Epub Date: 2025-07-19 DOI: 10.3892/or.2025.8951

Xiaoqun Zhu, Lizhou Jia, Xingwang Kuai, Qi Tang, Xinxia Chang, Xiao Zhang, Bing Chen, Hui Zhi, Haoran Hu, Xiaomei Huang, Zhenqing Feng, Wenbin Huang

{"title":"High expression of eIF4A1 promotes angiogenesis through the NF‑κB/VEGFA pathway and predicts poor prognosis in gastric cancer.","authors":"Xiaoqun Zhu, Lizhou Jia, Xingwang Kuai, Qi Tang, Xinxia Chang, Xiao Zhang, Bing Chen, Hui Zhi, Haoran Hu, Xiaomei Huang, Zhenqing Feng, Wenbin Huang","doi":"10.3892/or.2025.8951","DOIUrl":"10.3892/or.2025.8951","url":null,"abstract":"Increased eukaryotic translation initiation factor 4A (eIF4A1) expression is observed in numerous types of cancer and is associated with carcinogenesis; however, little is known about the role of eIF4A1 in gastric cancer (GC) angiogenesis. In the present study, a total of 1,758 gastric mucosa samples were collected for immunohistochemical staining in tissue microarrays. The expression levels of eIF4A1 and their association with clinicopathological characteristics and prognosis were analyzed using χ2 test and univariate/multivariate analysis. The effects of abnormal eIF4A1 expression in GC cells on proangiogenic activity was detected using the Cell Counting Kit‑8 proliferation assay, wound healing assay, Transwell assay, angiogenesis assay and a subcutaneous tumor model. The role of eIF4A1 in tumor‑infiltrating lymphocytes was explored using bioinformatics analysis. Furthermore, the effect of eIF4A1 on proangiogenic factors was confirmed by the quantitative polymerase chain reaction and western blotting. Notably, eIF4A1 was highly expressed in GC tissues, and was associated with patient age, tumor differentiation, depth of invasion, distant metastasis and Tumor‑Node‑Metastasis stage. Furthermore, it was suggested that high eIF4A1 expression could be regarded as a poor prognostic biomarker for patients with GC. The expression levels of eIF4A1 in GC cells were also positively related to proliferation, migration and the tube formation of human umbilical vein endothelial cells, and microvessel density in vivo. Furthermore, eIF4A1 in GC cells regulated the infiltration of immune cells in the tumor microenvironment, and promoted the expression of VEGFA and NF‑κB. In conclusion, eIF4A1 may promote GC angiogenesis through the NF‑κB/VEGFA pathway, and could be considered an independent prognostic biomarker for patients with GC.","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"54 4","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308842/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144668061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Retracted] Twist induces epithelial‑mesenchymal transition in cervical carcinogenesis by regulating the TGF‑β/Smad3 signaling pathway. [回缩]Twist通过调节TGF - β/Smad3信号通路诱导宫颈癌发生中的上皮-间质转化。

IF 3.9 3区医学

Oncology reports Pub Date : 2025-10-01 Epub Date: 2025-08-01 DOI: 10.3892/or.2025.8960

Qiong Fan, Mei-Ting Qiu, Zhu Zhu, Jin-Hua Zhou, Limo Chen, Ye Zhou, Wei Gu, Li-Hua Wang, Zhu-Nan Li, Ying Xu, Wei-Wei Cheng, Dan Wu, Wei Bao

{"title":"[Retracted] Twist induces epithelial‑mesenchymal transition in cervical carcinogenesis by regulating the TGF‑β/Smad3 signaling pathway.","authors":"Qiong Fan, Mei-Ting Qiu, Zhu Zhu, Jin-Hua Zhou, Limo Chen, Ye Zhou, Wei Gu, Li-Hua Wang, Zhu-Nan Li, Ying Xu, Wei-Wei Cheng, Dan Wu, Wei Bao","doi":"10.3892/or.2025.8960","DOIUrl":"https://doi.org/10.3892/or.2025.8960","url":null,"abstract":"Following the publication of this paper, it was drawn to the Editor's attention by a concerned reader that, for the Transwell migration and invasion assay experiments shown in Fig. 3C and D on p. 1791, two pairs of the data panels appeared to be overlapping, suggesting that the same data may have been used in this figure to represent data that were intended to show the results from differently performed experiments. Although the authors responded to the original emailed request from the Editorial Office concerning these data and repeated the experiments shown in this figure, upon performing an independent analysis of the original (published) figures in the office, it came to light that Figs. 1 and 4 also contained probable anomalies. In Fig. 1C and D, there were cells/small areas of the images located in the bottom left hand corners of the images that were strikingly similar, to the extent that this would have been difficult to attribute to coincidence. Furthermore, in the case of Fig. 4, the gel slices in Fig. 4B showed evidence of possible cutting‑and‑splicing events. Owing to the fact that these probable anomalies were also identified that could have affected the interpretation of two additional figures in the published article, the Editor of Oncology Reports has decided that this paper should be retracted from the Journal due to a lack of confidence in the presented data. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a satisfactory reply. The Editor apologizes to the readership for any inconvenience caused. [Oncology Reports 34: 1787‑1794, 2015; DOI: 10.3892/or.2015.4143].","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"54 4","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144760663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of miRNA‑214‑3p in cancer (Review). miRNA - 214 - 3p在癌症中的作用（综述）。

IF 3.9 3区医学

Oncology reports Pub Date : 2025-10-01 Epub Date: 2025-08-01 DOI: 10.3892/or.2025.8957

Zeshan Chen, Xin Deng, Yuanhong Lu, Ling Lu, Yijue Qin, Haishun Qu, Shaohang Lan

引用次数: 0

Potential therapeutic target in oncology: Protein palmitoylation (Review). 肿瘤的潜在治疗靶点：蛋白棕榈酰化（综述）。

IF 3.9 3区医学

Oncology reports Pub Date : 2025-10-01 Epub Date: 2025-07-19 DOI: 10.3892/or.2025.8950

Shiping Hao, Yongming Mei, Shaolin Chen, Jing Liu, Yao Zhang, Zhengfeng Zhu, Kangjia Zuo

{"title":"Potential therapeutic target in oncology: Protein palmitoylation (Review).","authors":"Shiping Hao, Yongming Mei, Shaolin Chen, Jing Liu, Yao Zhang, Zhengfeng Zhu, Kangjia Zuo","doi":"10.3892/or.2025.8950","DOIUrl":"10.3892/or.2025.8950","url":null,"abstract":"Post‑translational modifications (PTMs) of proteins, by altering the structural conformation of precursor polypeptides, play an indispensable role in augmenting the diversity and stability of the proteome. PTMs exert profound influence on various hallmarks of tumor biology, including cellular proliferation, apoptosis, angiogenesis and metastatic dissemination. Accordingly, advancing our understanding of PTMs holds substantial promise for broadening the therapeutic landscape of oncology. Among these modifications, palmitoylation, a reversible lipid‑based PTM, critically modulates protein stability, membrane localization, protein‑protein interactions and signal transduction cascades. Dysregulation of palmitoylation has been increasingly implicated in tumorigenesis, suggesting its aberrant forms as putative targets for therapeutic intervention. The present review delineates the biochemical mechanisms underlying protein palmitoylation and synthesizes current insights into its multifaceted roles in tumor progression, immune modulation and metabolic regulation, thereby offering novel perspectives for the development of targeted cancer therapies.","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"54 4","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144668063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

O‑GlcNAcylation as an emerging molecular target for cholangiocarcinoma therapy (Review). O - glcn酰化作为胆管癌治疗的新兴分子靶点（综述）。

IF 3.9 3区医学

Oncology reports Pub Date : 2025-10-01 Epub Date: 2025-07-19 DOI: 10.3892/or.2025.8952

Purin Charoensuksai, Siwanon Jirawatnotai

{"title":"O‑GlcNAcylation as an emerging molecular target for cholangiocarcinoma therapy (Review).","authors":"Purin Charoensuksai, Siwanon Jirawatnotai","doi":"10.3892/or.2025.8952","DOIUrl":"10.3892/or.2025.8952","url":null,"abstract":"Aberrant O‑GlcNAcylation and the upregulation of O‑GlcNAc transferase (OGT) are key contributors to cancer pathogenesis and progression, driving hyperproliferative states and metastatic phenotypes. Targeting OGT may suppress cancer progression, positioning OGT and O‑GlcNAc signaling as compelling targets in cancer research. Cholangiocarcinoma (CCA), a rare yet highly aggressive malignancy of the bile duct system, represents a clinical challenge, underscored by its rising global mortality, poor survival outcomes and high recurrence rate, despite advances in awareness, diagnostics and therapeutic strategies. Consequently, there is need for novel therapeutic modalities. Hyperactive O‑GlcNAcylation and upregulation of OGT are observed in CCA, therefore, targeting protein O‑GlcNAcylation may have clinical potential. The present review aimed to summarize the impact of O‑GlcNAcylation on CCA and CCA‑relevant hallmarks of cancer including cell proliferation, metastasis, metabolic reprogramming, angiogenesis, programmed cell death and tumor‑associated inflammation. In areas where direct evidence in CCA is limited, insights from other gastrointestinal tract cancers may identify potential mechanistic connections, offering a broader context to guide future investigation. Furthermore, the viability of OGT and O‑GlcNAcylation as therapeutic targets is discussed.","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"54 4","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144668062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Retracted] Upregulation of GRIM‑19 suppresses the growth of oral squamous cell carcinoma in vitro and in vivo. [撤回]在体外和体内，上调GRIM - 19抑制口腔鳞状细胞癌的生长。

IF 3.9 3区医学

Oncology reports Pub Date : 2025-10-01 Epub Date: 2025-07-25 DOI: 10.3892/or.2025.8955

Minghe Li, Zhihong Li, Chongyang Liang, Chengmin Han, Wei Huang, Fei Sun

{"title":"[Retracted] Upregulation of GRIM‑19 suppresses the growth of oral squamous cell carcinoma in vitro and in vivo.","authors":"Minghe Li, Zhihong Li, Chongyang Liang, Chengmin Han, Wei Huang, Fei Sun","doi":"10.3892/or.2025.8955","DOIUrl":"10.3892/or.2025.8955","url":null,"abstract":"Following the publication of this paper, it was drawn to the Editor's attention by a concerned reader that certain of the western blot data shown in Figs. 1C and 5C on p. 2186 and p. 2188 respectively were strikingly similar to data that had already been published in articles written by different authors at different research institutes, or which had been included in articles that were already under consideration for publication. Upon investigating this matter independently in the Editorial Office, we were able to confirm the reader's concerns. Therefore, due to the fact that the contentious western blot data in the above article had already been published prior to its submission to Oncology Reports, the Editor has decided that this paper should be retracted from the Journal. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a reply. The Editor apologizes to the readership for any inconvenience caused. [Oncology Reports 32: 2183‑2190, 2014; DOI: 10.3892/or.2014.3423].","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"54 4","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308832/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144708397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Breaking therapeutic barriers in solid tumors: Clinical progress of antibody‑drug conjugate/immune checkpoint inhibitor combinations (Review). 打破实体瘤的治疗障碍：抗体-药物偶联物/免疫检查点抑制剂联合的临床进展（综述）。

IF 3.9 3区医学

Oncology reports Pub Date : 2025-10-01 Epub Date: 2025-08-01 DOI: 10.3892/or.2025.8956

Yang Zheng, Yangxuan Ding, Longxia Chen, Zengrui Zhang, Ruilin Ding

引用次数: 0

Chromosome 20q gene signature associated with colorectal cancer progression. 染色体20q基因标记与结直肠癌进展相关

IF 3.9 3区医学

Oncology reports Pub Date : 2025-10-01 Epub Date: 2025-07-19 DOI: 10.3892/or.2025.8954

Jennifer Carter Jones, Apurva M Hegde, Yu-Jing Huang, Ganiraju Manyam, Vibhuti Srivastava, Jee Hoo Song, Yulan Cheng, Ralf Krahe, Warapen Treekitkarnmongkol, Stephen J Meltzer, Scott Kopetz, Stanley R Hamilton, Hiroshi Katayama, Subrata Sen

{"title":"Chromosome 20q gene signature associated with colorectal cancer progression.","authors":"Jennifer Carter Jones, Apurva M Hegde, Yu-Jing Huang, Ganiraju Manyam, Vibhuti Srivastava, Jee Hoo Song, Yulan Cheng, Ralf Krahe, Warapen Treekitkarnmongkol, Stephen J Meltzer, Scott Kopetz, Stanley R Hamilton, Hiroshi Katayama, Subrata Sen","doi":"10.3892/or.2025.8954","DOIUrl":"10.3892/or.2025.8954","url":null,"abstract":"Amplification of human chromosome 20q has been reported as the most frequently recurring genetic abnormality associated with large scale changes in mRNA and protein levels in sporadic colorectal carcinomas. While some studies have found 20q amplification to be consistent between primary and metastatic samples from the same patient with a role in the development of metastasis and worse patient prognosis, others have reported association with improved overall survival for a subset of these patients with colorectal cancer (CRC). To fine map the Minimal Common Regions (MCRs) of amplification on chromosome 20q and identify the candidate genes playing roles in progression of the disease, microarray comparative genomic hybridization analyses of two in vitro cultured CRC liver metastasis cell line model systems was utilized. Microarray expression analysis led to the identification of a candidate gene signature comprising of four genes, BMP7, DNMT3B, UBE2C and YWHAB, residing in the MCRs that were over expressed in CRC cells. By validating our results in a training set of 23 adenocarcinomas (tumors) and five adenomas (polyps) using reverse transcription‑quantitative PCR, as well as analyses of two larger colorectal cancer test data sets derived from 195 The Cancer Genome Atlas and 182 MD Anderson Cancer Center patients with colorectal adenocarcinoma patients, this gene signature was ascertained to be associated with lymph node spread and/or distant metastasis (P<0.05). Previously reported functional studies of the gene signature indicated their involvement in inflammatory and immune response pathways driving CRC progression.","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"54 4","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308843/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144668060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Corrigendum] Human chorionic gonadotropin β regulates epithelial‑mesenchymal transition and metastasis in human ovarian cancer. [勘误]人绒毛膜促性腺激素β调节人卵巢癌上皮-间充质转移和转移。

IF 3.9 3区医学

Oncology reports Pub Date : 2025-10-01 Epub Date: 2025-07-19 DOI: 10.3892/or.2025.8948

Na Liu, Shu-Min Peng, Guang-Xi Zhan, Jing Yu, Wei-Min Wu, Hao Gao, Xiao-Feng Li, Xiao-Qing Guo

{"title":"[Corrigendum] Human chorionic gonadotropin β regulates epithelial‑mesenchymal transition and metastasis in human ovarian cancer.","authors":"Na Liu, Shu-Min Peng, Guang-Xi Zhan, Jing Yu, Wei-Min Wu, Hao Gao, Xiao-Feng Li, Xiao-Qing Guo","doi":"10.3892/or.2025.8948","DOIUrl":"10.3892/or.2025.8948","url":null,"abstract":"Following the publication of the above article, an interested reader drew to the Editor's attention that, for the scratch‑wound assay experiments shown in Fig. 3 on p. 1468, the \"ES‑2 LV‑β‑hCG\" and \"ES‑2 siRNA‑β‑hCG\" data panels were apparently the same, suggesting that the same data panel had erroneously been included twice in this figure. Furthermore, β‑actin blots featured in Fig. 2C on p. 1467, and certain of the western blot data featured in Fig. 6A on p. 1470, were strikingly similar to western blot data that appeared in papers subsequently published by the same research group in the journals Cell Cycle and Cancer Science, respectively; finally, the same western blot data had been selected to represent β‑catenin and Slug protein bands in Fig. 6A. After having examined their original data, the authors realized that these figures had been inadvertently assembled incorrectly. The revised versions of Fig. 2 (showing all the correct β‑actin data in Fig. 2C), Fig. 3 (showing the correct data for the \"ES‑2 siRNA‑β‑hCG\" experiment) and Fig. 6 (showing the correct data for the \"Slug/ES‑2 siRNA‑β‑hCG\" and \"Slug/SKOV3 siRNA‑β‑hCG\" protein bands) are shown on the next two pages. Note that the revisions made to these figures do not affect the overall results and conclusions reported in the paper. The authors are grateful to the Editor of Oncology Reports for granting them the opportunity to publish this corrigendum, and all the authors agree with its publication; furthermore, they apologize to the readership of the journal for any inconvenience caused. [Oncology Reports 38: 1464‑1472, 2017; DOI: 10.3892/or.2017.5818].","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"54 4","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308833/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144668058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0